Physician profile
Peter A Azar
NPI 1316935380
$587.44
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $76.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.02 | 2019 | |
| Pfizer INC. | $123.00 | 2019-2020 | |
| Novo Nordisk INC | $58.62 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.41 | 2019-2020 | |
| Amgen INC. | $32.07 | 2019 | |
| Merck Sharp & Dohme LLC | $31.98 | 2019-2020 | |
| Lilly USA, LLC | $25.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.64 | 2020 | |
| Glaxosmithkline, LLC. | $20.06 | 2019 | |
| Circassia INC. | $19.43 | 2019 | |
| Amarin Pharma, INC. | $17.65 | 2019 | |
| Sanofi Pasteur INC. | $17.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.